BR112015022263A2 - N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica - Google Patents
N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêuticaInfo
- Publication number
- BR112015022263A2 BR112015022263A2 BR112015022263A BR112015022263A BR112015022263A2 BR 112015022263 A2 BR112015022263 A2 BR 112015022263A2 BR 112015022263 A BR112015022263 A BR 112015022263A BR 112015022263 A BR112015022263 A BR 112015022263A BR 112015022263 A2 BR112015022263 A2 BR 112015022263A2
- Authority
- BR
- Brazil
- Prior art keywords
- ureas
- pyridin
- anticancer
- fms
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
abstract described are compounds of formula i formula i which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. these compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases. ______________________________________________________ resumo n-acil-n'-(piridin-2-il) ureias e análogos apresentando atividades anticâncer e antiproliferativas são descritos compostos de fórmula i fórmula i que encontram utilidade no tratamento de câncer, doenças autoimunes e distúrbios metabólicas do osso, através da inibição de c-fms (csf-ir), c-kit, e/ou quinases pdgfr. estes compostos também encontram utilidade no tratamento de outras doenças de mamíferos mediadas por c-fms, c-kit, ou quinases pdgfr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361789971P | 2013-03-15 | 2013-03-15 | |
US61/789,971 | 2013-03-15 | ||
PCT/US2014/029664 WO2014145028A2 (en) | 2013-03-15 | 2014-03-14 | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015022263A2 true BR112015022263A2 (pt) | 2017-10-10 |
BR112015022263A8 BR112015022263A8 (pt) | 2018-01-23 |
BR112015022263B1 BR112015022263B1 (pt) | 2023-01-03 |
Family
ID=51529946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022263-3A BR112015022263B1 (pt) | 2013-03-15 | 2014-03-14 | N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (1) | US9382228B2 (pt) |
EP (1) | EP2968287B1 (pt) |
JP (3) | JP6364472B2 (pt) |
KR (2) | KR102333718B1 (pt) |
CN (3) | CN105228620B (pt) |
AU (2) | AU2014233414B2 (pt) |
BR (1) | BR112015022263B1 (pt) |
CA (1) | CA2903288C (pt) |
ES (1) | ES2817902T3 (pt) |
HK (1) | HK1220400A1 (pt) |
IL (2) | IL241523B (pt) |
MX (2) | MX366429B (pt) |
PH (1) | PH12015502336A1 (pt) |
RU (1) | RU2769607C2 (pt) |
SG (1) | SG11201508532VA (pt) |
WO (1) | WO2014145028A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5335056B2 (ja) | 2011-11-16 | 2013-11-06 | 住友電気工業株式会社 | ボルト用アルミニウム合金線及びボルト並びにそれらの製造方法 |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
RU2769607C2 (ru) * | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность |
TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
KR101691954B1 (ko) * | 2016-04-26 | 2017-01-02 | 고려대학교 산학협력단 | 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물 |
EP3632907B1 (en) * | 2017-05-24 | 2024-02-28 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
CN110461849B (zh) * | 2017-06-19 | 2020-09-01 | 上海和誉生物医药科技有限公司 | 一种csf1r抑制剂及其制备方法和应用 |
KR20200040295A (ko) * | 2017-08-24 | 2020-04-17 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
CN109776401A (zh) * | 2017-11-14 | 2019-05-21 | 成都博腾药业有限公司 | 一种制备6-氯-5-三氟甲基-2-氨基吡啶的方法 |
CN110845476B (zh) * | 2018-08-21 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用 |
DK3902547T3 (da) | 2018-12-28 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Csf1r-hæmmere til anvendelse i cancerbehandling |
HUE064734T2 (hu) | 2019-02-06 | 2024-04-28 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok |
EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
LT3966206T (lt) | 2019-05-10 | 2023-11-10 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidino amido autofagijos inhibitoriai ir jų naudojimo būdai |
EP3983081A1 (en) | 2019-06-17 | 2022-04-20 | Deciphera Pharmaceuticals, LLC | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
RS65058B1 (sr) | 2019-12-30 | 2024-02-29 | Deciphera Pharmaceuticals Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primene |
BR112022013169A2 (pt) | 2019-12-30 | 2022-09-13 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea |
US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
CN115385896A (zh) * | 2021-05-24 | 2022-11-25 | 上海和誉生物医药科技有限公司 | 一种csf-1r抑制剂中间体或其酸式盐的制备方法 |
TW202300142A (zh) * | 2021-05-24 | 2023-01-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA861446B (en) * | 1985-03-01 | 1986-10-29 | Duphar Int Res | Benzoyl urea derivatives having anti-tumor activity |
CN100415720C (zh) * | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
DE602006021645D1 (de) * | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
CA2672438A1 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
BRPI0920765A2 (pt) * | 2008-10-29 | 2015-08-18 | Deciphera Pharmaceuticals Llc | Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas |
RU2769607C2 (ru) * | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность |
-
2014
- 2014-03-14 RU RU2015143718A patent/RU2769607C2/ru not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/029664 patent/WO2014145028A2/en active Application Filing
- 2014-03-14 CN CN201480026796.6A patent/CN105228620B/zh active Active
- 2014-03-14 CN CN202010826889.4A patent/CN112047927A/zh active Pending
- 2014-03-14 BR BR112015022263-3A patent/BR112015022263B1/pt active IP Right Grant
- 2014-03-14 JP JP2016503187A patent/JP6364472B2/ja active Active
- 2014-03-14 MX MX2015013404A patent/MX366429B/es active IP Right Grant
- 2014-03-14 EP EP14764601.2A patent/EP2968287B1/en active Active
- 2014-03-14 US US14/214,185 patent/US9382228B2/en active Active
- 2014-03-14 KR KR1020157029126A patent/KR102333718B1/ko active IP Right Grant
- 2014-03-14 CN CN201910586017.2A patent/CN110563700A/zh active Pending
- 2014-03-14 ES ES14764601T patent/ES2817902T3/es active Active
- 2014-03-14 AU AU2014233414A patent/AU2014233414B2/en active Active
- 2014-03-14 SG SG11201508532VA patent/SG11201508532VA/en unknown
- 2014-03-14 CA CA2903288A patent/CA2903288C/en active Active
- 2014-03-14 KR KR1020217038874A patent/KR102386952B1/ko active IP Right Grant
-
2015
- 2015-09-10 IL IL24152315A patent/IL241523B/en active IP Right Grant
- 2015-09-17 MX MX2019008003A patent/MX2019008003A/es unknown
- 2015-10-08 PH PH12015502336A patent/PH12015502336A1/en unknown
-
2016
- 2016-07-19 HK HK16108586.5A patent/HK1220400A1/zh unknown
-
2018
- 2018-07-02 JP JP2018126337A patent/JP2018184416A/ja active Pending
- 2018-09-24 AU AU2018236691A patent/AU2018236691B2/en active Active
-
2019
- 2019-09-19 IL IL269451A patent/IL269451B/en unknown
-
2020
- 2020-04-07 JP JP2020068792A patent/JP6985448B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022263A2 (pt) | N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica | |
AU2024202088A1 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
WO2014145029A3 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
WO2014145015A3 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
BR112016005270A2 (pt) | compostos de aza-piridona, composições farmacêuticas e seus usos | |
MY189761A (en) | Quinazoline derivatives used to treat hiv | |
EA201591051A1 (ru) | Ингибиторы erk и варианты их применения | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
BR112019000692A8 (pt) | Moduladores de somatostatina e usos destes | |
BR112015006029A2 (pt) | compostos aza bicíclicos como agonistas de receptor m1 muscarínicos | |
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
BR112013022761B8 (pt) | Compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos | |
BR112014029310A2 (pt) | análogos da pirimidina heterocíclica como inibidores da tyk2 | |
BR112017009583A2 (pt) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 | |
BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
MD3386991T2 (ro) | Compuși policiclici ca inhibitori de tirozin kinază Bruton | |
BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS |